CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...
The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...
Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than ...
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the ...
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a ...
Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the ...
The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results